Kevin Caldwell

In a new @ClinicalLeader1 interview, our CEO @KevinCaldweII explains why Ossium took a multi-center approach from its earliest study. To date, 29 patients have been treated with Ossium’s organ donor-derived bone marrow at roughly half as many centers, each using the conditioning regimens and post-transplant care its team already knew. The goal was to generate data that reflects real-world transplant practice. We're now carrying that approach into PRESERVE II, a 300-patient, three-arm study that begins enrollment in 2027. Read the full interview: clinicalleader.com/doc/ossiu…

This week, @AABB selected Ossium’s abstract, "On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors," as a Top Poster at the 2026 Annual Meeting. The findings show stem cell viability preserved through cryopreservation and 100% engraftment in evaluable transplant recipients. Attending #AABB2026? Join the Ossium team on the Curated Top Posters Tour: Innovations in Cellular Therapies, Sunday, Oct. 18, 12:15–1 p.m. ET, Biotherapies Pavilion. Read the full release: globenewswire.com/news-relea…

Last week we welcomed @RepHouchin, who represents Indiana's 9th District and serves on the House Energy and Commerce Committee, to our Indianapolis facility. Rep. Houchin toured our lab and met the team processing and banking bone marrow from deceased organ donors, and learned about how the process works end to end — from recovery through cryopreservation to a patient's bedside. We're grateful for her time and her interest in the patients this work is for.

We’re proud to have been named as a winner of the @Inc 2023 Best in Business award! This award honors dynamic companies making an extraordinary positive impact on their communities, their industries, the environment, or society as a whole #bestinbusiness inc.com/best-in-business

We're excited to announce our partnership with @ExCellThera! Read more about how @OssiumHealth's world first bone marrow bank and ExCellThera’s cell expansion and rejuvenation technology can improve human health: globenewswire.com/news-relea…

Nasdaq congratulates us on our Series B fundraising from Times Square! #Nasdaq #Biotechnology

@OssiumHealth and Columbia University Irving Medical Center initiate Phase 1 study using bone marrow stem cells to minimize immunosuppression requirements in intestinal transplantation. Read more about it here: ossiumhealth.com/ossium-heal… #ossiumhealth #columbiauniversity

We're excited to announce the completion of our Series B funding raising $63 million! Read more about our pursuit to improve treatment of blood and immune diseases using stem cell science in The Wall Street Journal @WSJ: wsj.com/articles/bioengineer… #ossiumhealth #wallstreetjournal